TERREMOTO Trademark

Trademark Overview

On Monday, September 20, 2021, a trademark application was filed for TERREMOTO with the United States Patent and Trademark Office. The USPTO has given the TERREMOTO trademark a serial number of 97035820. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Friday, February 9, 2024. This trademark is owned by Seismic Medicines, Inc.. The TERREMOTO trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceuticals for the prevention and treatment of cancer, oncological diseases, disorders and conditions; pharmaceuticals for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; pharmaceutical preparations and substances for the prevention and treatment of cancer, oncological diseases, disorders and conditions;pharmaceutical preparations and substances for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; biopharmaceuticals for the prevention and treatment of cancer, oncological diseases, disorders and conditions; biopha...
terremoto

General Information

Serial Number97035820
Word MarkTERREMOTO
Filing DateMonday, September 20, 2021
Status730 - FIRST EXTENSION - GRANTED
Status DateFriday, February 9, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 20, 2023

Trademark Statements

Goods and Servicespharmaceuticals for the prevention and treatment of cancer, oncological diseases, disorders and conditions; pharmaceuticals for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; pharmaceutical preparations and substances for the prevention and treatment of cancer, oncological diseases, disorders and conditions;pharmaceutical preparations and substances for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; biopharmaceuticals for the prevention and treatment of cancer, oncological diseases, disorders and conditions; biopharmaceuticals for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; medicines for the prevention and treatment of cancer, oncological diseases, disorders and conditions; medicines for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; drugs for the prevention and treatment of cancer, oncological diseases, disorders and conditions;drugs for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; drug compounds for the prevention and treatment of cancer, oncological diseases, disorders and conditions;drug compounds for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; small molecules for the prevention and treatment of cancer, oncological diseases, disorders and conditions;small molecules for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions; therapeutics for the prevention and treatment of cancer, oncological diseases, disorders and conditions;therapeutics for the prevention and treatment of genetic, inflammatory, infectious, viral, immune system, immunological, autoimmune, blood, hematologic, ophthalmological, cardiovascular, cardiopulmonary, metabolic, kidney, liver, vascular, endocrine, and dermatologic diseases, disorders and conditions
Translation of Words in MarkThe English translation of "TERREMOTO" in the mark is "earthquake".

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, May 11, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTERREMOTO BIOSCIENCES, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080
Party NameTERREMOTO BIOSCIENCES, INC.
Party Type12 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressSAN FRANCISCO, CA 94158
Party NameTERREMOTO BIOSCIENCES, INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressSan Francisco, CA 94158
Party NameSeismic Medicines, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMenlo Park, CA 94025

Trademark Events

Event DateEvent Description
Saturday, February 10, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, February 9, 2024SOU EXTENSION 1 GRANTED
Friday, February 9, 2024SOU EXTENSION 1 FILED
Friday, February 9, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 15, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, June 20, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 20, 2023PUBLISHED FOR OPPOSITION
Wednesday, May 31, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, May 11, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, May 11, 2023EXAMINER'S AMENDMENT ENTERED
Thursday, May 11, 2023NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, May 11, 2023EXAMINERS AMENDMENT E-MAILED
Thursday, May 11, 2023EXAMINERS AMENDMENT -WRITTEN
Wednesday, January 25, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, November 16, 2022NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, November 16, 2022FINAL REFUSAL E-MAILED
Wednesday, November 16, 2022FINAL REFUSAL WRITTEN
Thursday, October 6, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 5, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 5, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, June 23, 2022AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, April 5, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, April 5, 2022NON-FINAL ACTION E-MAILED
Tuesday, April 5, 2022NON-FINAL ACTION WRITTEN
Friday, March 25, 2022ASSIGNED TO EXAMINER
Saturday, October 23, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, September 23, 2021NEW APPLICATION ENTERED

Related Keywords

terremoto conditions disorders diseases treatment prevention cancer oncological liver kidney cardiopulmonary